Engflag

Verruca Hermal

Quick links to important sections

Verruca Hermal

Verruca Hermal_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Verruca Hermal

Property Description
Active Ingredients Fluorouracil and Salicylic Acid
Form Topical Solution (Liquid)
Pharmacological Class Antimetabolite (Cytostatic) and Keratolytic Agent
Route of Administration Cutaneous (Applied to the skin)
Origin Synthetic Combination Product

What Type of Medicine is Verruca Hermal?

Verruca Hermal is a specialized topical solution formulated as a combination preparation for cutaneous application, designed to treat warts (verrucae). It is classified by its pharmacological class as an Antimetabolite (Cytostatic) and Keratolytic Agent combination. This combination approach is clinically recognized for addressing the complexity of hyperkeratotic lesions by targeting both viral growth and tissue buildup. The product is typically available as a prescription-only medication, distinguishing it from simpler over-the-counter keratolytic treatments.

What Active Ingredients Make Up Verruca Hermal?

The preparation's composition is defined by its two primary active ingredients: Fluorouracil (5-FU) and Salicylic Acid. Fluorouracil is the cytostatic agent component, an antineoplastic pyrimidine analog that acts by interfering with cell proliferation. Salicylic Acid is the keratolytic agent and salicylate, functioning to soften and promote the shedding (desquamation) of the thickened skin. The simultaneous delivery of these two agents in the topical solution form is a core composition feature, designed to maximize efficacy by improving the penetration of the Fluorouracil into the deeper wart tissue.

What is the General Purpose of This Combination Preparation?

The general purpose of Verruca Hermal is to systematically break down and resolve common warts and plantar warts using a synergistic chemical approach. The dual-action mechanism ensures that the treatment not only chemically targets the abnormal growth of cells but also facilitates the complete removal of the external hyperkeratotic mass. This provides a focused, non-systemic approach for the resolution of verrucae, particularly for persistent lesions where physical removal is not immediately suitable.

Regulatory References

  1. Antineoplastic Agents - LiverTox - NCBI Bookshelf
  2. Fluorouracil Topical: MedlinePlus Drug Information

What side effects are possible with Verruca Hermal?

Possible Side Effects and Safety Information

The safety profile of Verruca Hermal, a combination of Fluorouracil (cytostatic) and Salicylic Acid (keratolytic), is defined by its action at the application site and specific systemic constraints detailed in regulatory documents.

Frequency-Classified Adverse Reactions

The most commonly expected adverse reactions are localized, reflecting the intended breakdown of tissue. These are classified by frequency in official regulatory summaries:

  • Very Common (ge 1/10): Local reactions including erythema, inflammation, irritation, burning sensation, pain, and itching at the application site.
  • Common (1/100 to <1/10): Skin erosion, oozing, crust formation, bleeding, and headache.
  • These local reactions are typically most intense at the start of therapy and are expected to lessen after the initial weeks of treatment.

Serious Adverse Reactions and Restrictions

Specific safety considerations address the potential for rare, severe systemic effects, leading to strict regulatory limitations:

Safety Constraint Population/Risk Official Statement Context
Embryofetal Toxicity Pregnancy Contraindicated due to risk of fetal harm from the Fluorouracil component.
DPD Deficiency Risk Enzyme Deficiency Contraindicated in individuals with Dihydropyrimidine Dehydrogenase (DPD) enzyme deficiency due to the risk of life-threatening systemic toxicity.
Salicylate Risk Children/Viral Illness Contraindicated in children/teenagers with acute viral illnesses (e.g., Varicella or Influenza) due to the risk of Reye's syndrome.
Application Site Mucous Membranes/Eyes Strictly restricted from contact with eyes and mucous membranes due to risk of severe local inflammation.

Use also requires caution and close monitoring in patients with poor circulation or sensory impairment, such as those with diabetes mellitus, to prevent undetected tissue damage.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of the Fluorouracil and Salicylic Acid topical solution is officially documented across two primary risk areas: local effects and systemic toxicity. Local overdose at the application site may present as excessive pain, burning, inflammation, and potentially progress to local ulceration or necrosis. Systemic toxicity can occur following accidental ingestion or high absorption through ulcerated skin, affecting the Gastrointestinal, Hematopoietic, and Central Nervous Systems.

When to Seek Urgent Help

Regulatory documents state that immediate medical attention is required for cases of accidental ingestion or if severe systemic signs manifest. These life-threatening signs include bloody diarrhea, severe abdominal pain, stomatitis (mouth sores), or seizures associated with the Salicylate component. Patients with Dihydropyrimidine Dehydrogenase (DPD) enzyme deficiency are noted as being at significantly increased risk for acute, fatal systemic toxicity from the Fluorouracil component.

Management and Monitoring

Management is limited to symptomatic and supportive care, as no specific antidote is known for the topical preparation. Upon confirmed systemic exposure, hospital monitoring is required. This often includes daily white cell counts to observe for delayed-onset complications such as neutropenia or thrombocytopenia, which are severe hematologic disorders documented in the official profile. Discontinue the product immediately if systemic signs are observed.

Therapeutic Uses of Verruca Hermal

Verruca Hermal is a topical application intended for the management of various manifestations of warts. This includes common warts (Verruca vulgaris), plantar warts (Verruca plantaris), and mosaic warts. It is used in situations requiring localized care to address skin lesions that are rough, raised, or flat. The key therapeutic effect is to facilitate the controlled breakdown of wart tissue, which may help mitigate associated localized discomfort or irritation. The active ingredients are formulated to provide local action on the affected skin.

“Timely and appropriate treatment can be beneficial in the management of wart symptoms.”

Quick Fact: Relief for Wart Symptoms

Eligibility and Restrictions for Use

The eligibility for using the topical solution Verruca Hermal is strictly defined by regulatory authorities due to the risks associated with its active ingredients, Fluorouracil and Salicylic Acid. Use is generally restricted to immunocompetent adults.

Contraindicated Populations

The medicine must not be used in the following groups, as per official labeling:

  • Patients with known Dihydropyrimidine Dehydrogenase (DPD) deficiency, which can lead to severe systemic toxicity.
  • Women who are pregnant or who cannot rule out pregnancy.
  • Patients concurrently receiving brivudine, sorivudine, or their analogues.
  • Patients with diabetes mellitus or impaired peripheral blood circulation.
  • Patients with renal failure or known hypersensitivity to any component.
  • Infants and babies.

Age and Physiological Status Rules

Population Regulatory Eligibility Status
Pediatric Use is not recommended or not established in children.
Lactation Contraindicated or not recommended; advised to cease treatment or nursing.
Skin Condition Must not be applied to broken, infected, bleeding, or irritated skin.

Eligibility is also restricted to application on small body surface areas (typically no larger than 25 cm^2) to limit potential systemic absorption.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation identifies specific medicinal product categories and agents that interact with this product, which contains fluorouracil and salicylic acid. These interactions define mandatory restrictions and require specific monitoring.

Interacting Medicinal Products / Categories Practical Regulatory Constraint
Antiviral Nucleoside Analogues (e.g., Brivudine, Sorivudine, and derivatives) Strictly Contraindicated. These agents are potent inhibitors of the enzyme Dihydropyrimidine Dehydrogenase (DPD), leading to a drastic, life-threatening increase in the systemic concentration and toxicity of fluorouracil. A time interval of at least 4 weeks must be observed between the use of this product and these antivirals.
Anticonvulsants (e.g., Phenytoin) Caution Advised. Use may lead to elevated plasma concentrations of phenytoin, which has been reported to cause symptoms of intoxication with systemic fluorouracil.
Methotrexate Caution Advised. Systemic absorption of the salicylic acid component may interact with methotrexate, necessitating careful consideration.
Sulphonylureas (Antidiabetic agents) Caution Advised. The absorbed salicylic acid component may interact with these agents, which are used to lower blood sugar levels.

Interaction Profile Summary The product's official interaction profile is structured around the potential for systemic exposure to its two active components. The contraindication with antiviral nucleoside analogues is the most severe constraint, based on the mechanistic inhibition of the fluorouracil-degrading DPD enzyme. Secondary interactions involving Phenytoin, Methotrexate, and Sulphonylureas are noted due to the possibility of drug level elevation or undesirable effects from absorbed components, which requires physician awareness and possible close monitoring.

Mechanism of Action

Molecular Blockade of Cell Replication

This mechanism is driven by Fluorouracil, which functions by targeting and irreversibly inhibiting the enzyme Thymidylate Synthase. By blocking this enzyme, the drug halts the synthesis of a critical component for DNA production, resulting in the arrest of cell proliferation and subsequent apoptosis within the actively multiplying cellular structure.

Chemical Disruption and Tissue Breakdown

The second domain involves Salicylic Acid, which exerts a keratolytic effect by chemically dissolving the protein-rich intercellular cement that binds the cells of the stratum corneum. This action causes the hyperkeratotic outer tissue to soften and exfoliate (desquamation), leading to the physical separation of the affected cellular structure.

Mechanistic Synergy and Penetration Enhancement

These two actions are complementary: the chemical disruption of the outer barrier by Salicylic Acid facilitates the delivery and localized concentration of the replication modulator (Fluorouracil) to the underlying cellular targets. This combined action provides a highly targeted, localized physiological effect on the tissue structure.

Dosage and Administration Information

How to Use Verruca Hermal: Official Administration Guidelines

This section outlines the official instructions for the administration of Verruca Hermal solution. These guidelines define the standardized procedure for topical application.

Administration Scope

Administration Detail Official Instruction
Route of Administration Cutaneous use (Topical application to the skin)
Dosing Schedule Apply one drop or a small amount of solution to cover each wart only.
Frequency Once or twice daily.
Maximum Duration Continue until the wart is removed, for a maximum period of up to 12 weeks.

Procedural Steps

The correct use of Verruca Hermal begins with proper skin preparation and adheres to a specific, repeated application sequence.

  1. Preparation: Wash the affected skin area and dry it thoroughly before each application. Soaking the wart in warm water for 5 minutes beforehand is permitted but optional.
  2. Application: Using the applicator or brush, apply the defined dose (one drop or small amount) only to the wart(s), taking care to avoid surrounding healthy skin.
  3. Drying: Allow the applied solution to dry completely.
  4. Repetition: Repeat the process once or twice daily as scheduled.
  5. Missed Dose: If an application is missed, continue the treatment as prescribed at the next scheduled time; do not apply a double dose.

The overall use protocol is structured to ensure direct delivery of the medicine to the target site, defining the specific dose, frequency, and a strict 12-week limit for continuous treatment.

Recent Clinical Evidence

Recent Clinical Evidence: Overview of Studies

Research has explored the use of Verruca Hermal (a combination of fluorouracil and salicylic acid) for the treatment of common warts (verruca vulgaris) and plantar warts (verruca pedis). Clinical investigations typically compare the combination therapy to monotherapy (using the components separately) or placebo.

Efficacy Data from Clinical Trials

A Cochrane review that analyzed randomized controlled trials (RCTs) suggested that topical treatment with salicylic acid is associated with positive outcomes for non-genital cutaneous warts compared to placebo. Subsequent studies have examined the combined use of salicylic acid with fluorouracil.

Study Comparison Observed Outcomes Treatment Duration
Combination (FU/SA) vs. Fluorouracil alone Complete clearance was observed more frequently in common and plantar warts with the combination treatment. Typically 1 to 3 months
Combination (FU/SA) vs. Conventional Application A descriptive study noted a higher clearance rate for periungual warts when a specific modified application method was used compared to conventional application. Specific to the study protocol

Safety and Tolerability Profile

The safety profile of the combination treatment is generally consistent with the known effects of the individual components. Trials have documented common, localized skin reactions at the application site. These adverse events are typically related to the destructive nature of the ingredients and may include symptoms such as pain, itching (pruritus), redness (erythema), and blistering.

Research continues to evaluate the safety and tolerability of the combination in various patient populations and for different types of wart lesions.

Frequently Asked Questions (FAQ)

Common questions about Verruca Hermal (FAQ)

Q: What is Verruca Hermal used for?

A: Verruca Hermal is indicated for the treatment of common warts and plantar warts (verrucae). Its components are generally understood to work by softening and breaking down the hardened skin tissue associated with these warts.

Q: How quickly does Verruca Hermal typically work?

A: Individual responses may vary. The time frame for wart removal with Verruca Hermal often depends on the size and location of the wart and the consistency of the application. Treatment can take several weeks. It is important to continue the process as directed.

Q: What are the main components of Verruca Hermal?

A: Verruca Hermal typically contains salicylic acid and lactic acid. Salicylic acid acts as a keratolytic agent, which assists in the gradual removal of the wart. Lactic acid is often included to further support this softening and peeling process.

Q: Can children use this product?

A: The suitability of Verruca Hermal for children should be evaluated by a qualified healthcare provider. Pediatric use may require specific guidance and supervision, and it is crucial to follow the instructions provided on the product labeling or by a professional.

How should Verruca Hermal be stored and disposed of?

Official Storage and Disposal Requirements

The storage and handling of Verruca Hermal solution must strictly adhere to regulatory requirements to maintain product stability and safety.

Storage Conditions

Constraint Requirement
Temperature Do not store above 25 C; do not refrigerate or freeze.
Container Integrity Keep the bottle tightly closed after every use; discard the product if crystals have formed.
Handling The solution is flammable while wet, so keep it securely away from open flames or fire.

Stability and Safety

Once the bottle is opened, the solution must not be used for more than 3 months.

For safety, the medicine must be stored out of the sight and reach of children and pets.

Disposal

Unused or expired Verruca Hermal solution must not be thrown away with household waste or poured into wastewater. Disposal should follow local regulatory requirements, which typically involve returning the medicine to a pharmacy for appropriate waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Verruca Hermal found in:

A-Z Index: